This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



EfficacyBOSULIF efficacy​​​​​​​EfficacyLinkLinkLinkLinkBFORE studyBYOND studyStudy 200SafetySafety dataDosingBosulif Dosing informationSupport & ResourcesSupport and ResourcesMaterials

Click here for BOSULIF® (bosutinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Safety dataA well-defined and manageable safety profile1Overall safety population (N=1372)1*

1% of the overall patient safety population discontinued due to diarrhoea1

Effective management of very common AEs: Diarrhoea1-3Please refer to the BOSULIF SmPC for full details of adverse eventsData are from patients who received one or more doses of study drug for either newly diagnosed CP CML or were resistant or intolerant to prior therapy with CP, AP, BP CML or Ph+ ALL.
The data shown include real-world data in addition to safety data from the BFORE trial and Study 200 (N=1372).
1103 of 1372 patients experienced diarrhoea. Median duration of any grade of diarrhoea.Median time to first event. Further information

Please refer to the BOSULIF SmPC for full details of adverse events.

Bosulif Summary of Product Characteristics Loading
AE=adverse event; ALL=acute lymphoblastic leukemia; ALT= alanine aminotransferase; AP=accelerated phase; AST=aspartate aminotransferase; BP=blast phase; CML=chronic myelogenous leukemia; CP=chronic phase; OD=once daily; Ph+=Philadelphia chromosome-positive; SmPC=Summary of Product Characteristics.
References:BOSULIF (bosutinib) Summary of Product Characteristics.National Cancer Institute. Gastrointestinal complications (PDQ)-health professional version. Accessed December 2022.Benson AB III, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918-2926.
PfizerPro Customer Service

Speak to a trusted member of our customer service team for support and information.

Contact us

If you are seeking answers that are not on this page, can Medical Information help?

Click here

Legal Category: S1A
Further information is available upon request

PP-BOS-IRL-0176. Date of Preparation December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.